A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RsqVD
  • Most Recent Events

    • 30 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Nov 2019.
    • 30 May 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2018.
    • 06 Dec 2016 Preliminary results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top